Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of “Buy” by Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned a consensus rating of “Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $39.80.

A number of equities analysts recently issued reports on the stock. Truist Financial boosted their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. B. Riley Financial raised their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Oppenheimer increased their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 in the last quarter. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. American Century Companies Inc. increased its stake in Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after acquiring an additional 37,954 shares during the period. Eagle Health Investments LP acquired a new position in Centessa Pharmaceuticals in the third quarter worth about $2,500,000. Royce & Associates LP bought a new position in Centessa Pharmaceuticals during the third quarter worth about $5,999,000. Federated Hermes Inc. acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at approximately $42,429,000. Finally, Avoro Capital Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Down 2.4%

Shares of CNTA stock opened at $28.70 on Monday. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a market cap of $4.19 billion, a PE ratio of -15.68 and a beta of 1.55. The stock has a 50 day moving average of $25.85 and a 200-day moving average of $25.04.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.